Inhibrx Inc (INBX)
34.90
-0.25
(-0.71%)
USD |
NASDAQ |
Mar 28, 16:00
35.01
+0.11
(+0.32%)
After-Hours: 20:00
Inhibrx Cash from Financing (TTM): 201.96M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 201.96M |
September 30, 2023 | 359.76M |
June 30, 2023 | 160.38M |
March 31, 2023 | 219.68M |
December 31, 2022 | 258.55M |
September 30, 2022 | 141.38M |
June 30, 2022 | 141.69M |
March 31, 2022 | 122.00M |
December 31, 2021 | 83.77M |
September 30, 2021 | 59.28M |
Date | Value |
---|---|
June 30, 2021 | 194.68M |
March 31, 2021 | 171.08M |
December 31, 2020 | 166.46M |
September 30, 2020 | 149.02M |
June 30, 2020 | 10.92M |
March 31, 2020 | 29.90M |
December 31, 2019 | 43.33M |
September 30, 2019 | 50.90M |
June 30, 2019 | 51.03M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
10.92M
Minimum
Jun 2020
359.76M
Maximum
Sep 2023
137.67M
Average
141.69M
Median
Jun 2022
Cash from Financing (TTM) Benchmarks
Johnson & Johnson | -15.82B |
Gilead Sciences Inc | -5.125B |
Outlook Therapeutics Inc | 5.120M |
Axonics Inc | -3.38M |
NovaBay Pharmaceuticals Inc | 4.971M |